The Test of Cuban Cancer Vaccine Will Be Held In The U.S.
American Roswell Park Cancer Institute concluded an agreement with the Cuban Molecular Immunology Centre for clinical trials of Cimavax cancer vaccines in the United States. In the future, the drug can be feristered by FDA (Food and Drug Administration).
As the executive director of the Roswell Park Cancer Institute says, the center's specialists are going to improve the vaccine to make it more effective.
Cuban scientists have been working on the development of a therapeutic vaccine against lung cancer for more than 25 years. The drug was approved for use in the country in 2011. As shown by the clinical studies, the application of Cimavax increases the average life expectancy of patients by 4-6 months.
Cimavax is an inhibitor of the epidermal growth factor (EGF), a protein that plays an important role in the growth and division of cells. The vaccine leads to the formation of antibodies that bind to the epidermal growth factor molecules and inhibit their interaction with the receptor, including those on the surface of tumor cells, thereby inhibiting tumor growth.
- Unique Vaccine Deprives The Drugs Of Their Main Properties
- Two Vaccines Against Ebola Have Successfully Passed Safety Test
- Pfizer Stopped Selling Pneumococcal Vaccine in China